Case report of tirzepatide-induced hepatotoxicity in a 60-year-old woman with T2DM and obesity who had previously tolerated semaglutide and liraglutide for 7 years without liver injury. Liver enzymes rose within 21 days of starting tirzepatide 2.5 mg, normalizing after discontinuation. Highlights a rare complication of tirzepatide that is distinct from GLP-1-only agents, raising awareness among clinicians prescribing incretin therapies—particularly relevant for patients switching between GLP-1 and GLP-1/GIP dual agonists.
Spaeth, Lauren D; Jordan, Kim M; Barlow, Mariah P; Cottrell, Daryl A